News

TCTMD talked to Dr. Paul Chan and Dr. Anezi Uzendu about the new study's findings.

In the past, many women born with a heart condition were told they would not be able to birth children safely.

KSHB talked to Dr. Mikhail Kosiborod, a cardiologist at Saint Luke’s Mid America Heart Institute and the study’s lead investigator, and Nancy Collins, a patient who was enrolled in the study.

The Kansas City Star talked to Bobby Olm-Shipman about the new services and additions patients can expect to see once the project is completed.

Leading up to the KC Kicks Cancer match, the players talked with patients about their journey and the importance of preventive screenings.

In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF).

The drug Wegovy eased issues for people with a type of heart problem, adding to the treatment’s benefits beyond weight loss.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

Medicine eased symptoms of a condition that can cause fatigue and shortness of breath.